WCN26-6703 Initial Experience with IV Belimumab in Lupus Nephritis patients with Acute Kidney Injury and Frequent Relapses: A Case Series from Single Tertiary University Hospital

Read full text Summarise with VIRAT
Authors: Khai Vern Poon, Chang Chuan Chew, Kok Peng Ng, Soo Kun Lim, Chee Keong Thye, Soo Ying Yew, Jun Min Em, Elisya Liyana Abdullah, Shok Hoon Ooi, Maisarah Jalalonmuhali, Wan Ahmad Hafiz Wan Md Adnan, Chew Ming Wong
+3 more Yee Wan Lee, Chye Chung Gan, Shian Feng Cheng
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Belimumab, a monoclonal antibody that inhibits B-cell activating factor (BAFF), is one of the recently approved biologic adjunct in the management of lupus nephritis (LN) following its robust efficacy from the BLISS-LN trial. However, real world data remain limited among LN patients with AKI (particularly those with eGFR < 30 mls/min/1.73m2) or those with frequent relapses. We aim to report our single center experience on the outcomes of IV belimumab in these two challenging LN cohorts.

Fields of Study & Subjects

Systemic Lupus Erythematosus Research Renal Diseases and Glomerulopathies Renal Transplantation Outcomes and Treatments

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106275–106275
Publication date
25 March 2026
Language
EN